News
-
The US FDA has notified Insmed that it has placed a clinical hold on Insmed’s trials of Arikace liposomal amikacin for inhalation. The ongoing Phase 3 program for the use of Arikace in cystic fibrosis… Read more . . .
-
A goal date of March 26, 2012 has been set for the NDA submitted to the FDA for MAP Pharmaceuticals’ Levadex inhaled dihydroergotamine (DHE) for the treatment of migraine in adults. The acceptance triggered a… Read more . . .
-
Minneapolis, MN area. This company is looking for someone with experience in any type of drug/device combinations, including OINDPs; it is dedicated to the development and commercialization of the safest, most efficacious drug coated balloon… Read more . . .
-
SkyePharma has announced that it has entered into a development, license, and marketing agreement for its Flutiform fluticasone and formoterol combination MDI with Sanofi in Mexico, Central America and South America. Sanofi will submit marketing… Read more . . .
-
According to the US Health and Human Service Department’s Agency for Healthcare Research and Quality (AHRQ), the average annual cost of prescription drugs to treat a child with asthma in the US rose from $349… Read more . . .
-
Armstrong Pharmaceuticals is advising customers to stockpile its Primatene Mist epinephrine MDI before the FDA ban on CFC formulations takes effect on December 31, 2011. The company says that it is “actively finalizing its internal… Read more . . .
-
According to Almirall, it has submitted a marketing authorization application to the European Medicines Agency (EMA) for its aclidinium bromide DPI for the treatment of COPD. Aclidinium bromide is a long-acting inhaled muscarinic antagonist; the… Read more . . .
-
Jim Nightingale has been promoted from Senior VP for Business Development and Strategic Alliances to President of drug development company Bend Research. Rod Ray is stepping down as President but will remain as CEO and… Read more . . .
-
A small portion of Gilead’s 11% increase in revenue for the second quarter of 2011 compared to the same quarter in 2010 is attributable to a 105% increase in the US sales of Cayston astreonam… Read more . . .
-
Mark Copley of Copley Scientific answers questions about upcoming changes to nebulizer testing requirements. Q: What are the new nebulizer testing requirements, and when do they come into force? A: Both the United States Pharmacopoeia… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan